Answers are grounded in this paper and cite their sources.
Preclinical evaluation demonstrates osteosarcoma growth inhibition and reduced bone resorption in mouse models, highlighting therapeutic potential for bone diseases.
New pyrazolo[3,4-d]pyrimidines were synthesized and found to inhibit Src phosphorylation in a cell-free assay. Some of them significantly reduced the growth of human osteogenic sarcoma (SaOS-2) cells. The best compound, in terms of inhibitory properties toward both Src and SaOS-2 cells, was further investigated and found to reduce bone resorption when used to treat mouse osteoclasts, without interfering with normal osteoblast growth. Moreover, its metabolic stability prompted its study on a human SaOS-2 xenograft tumor model in nude mice, where the compound reduced significantly both the volume and weight of the tumor. These experimental findings make the new compound an interesting hit in the field of bone-related diseases.
No takes yet. Share an insight, caveat, or question.
Manetti et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: